SHAFAQNA (International Shia News Association) – The Food and Drug Administration approved two new drugs that can slow the spread of fatal lung disease.
The approved drugs, Boehringer Ingelheim’s Ofev and Roche’s Esbriet, are made to cure a lung scarring called as idiopathic pulmonary fibrosis. This disease takes the patient’s life in three to five years; these drugs cannot eliminate the diseases totally and only slow down the disease progression.
“It’s very exciting to have two approved therapies now for a disease for which there were no approved therapies,” said Daniel M. Rose, chief executive of the Pulmonary Fibrosis Foundation.
The cost of Roche’s Esbriet would be over $7,800 in a month or $94,000 in a year. The price of Ofev had not been disclosed and Boehringer executives reported that the price would be disclosed when the drug became available.
The sky high price tag on Roche’s drug concerned experts. A spokesman for Roche reported that price of the drug was set on the basis of diverse factors, including the drug efficiency and price of other drugs for serious lung conditions.
Both drugs got their approval prior to their deadlines. For Esbriet, it was November 23 and for Ofev, it was January 2.
This indicated the need of the drug in the market as this disease affects the person’s breathing ability.
Esbriet and pirfenidone are also known as pirfenidone and nintedanib respectively. The exact functioning of both drugs is unknown but they both slow the disease progression.